RZRebecca ZashMDVideoHIVGlobal HIV Clinical Forum 2018Implication of the resent Dolutegravir data | Rebecca Zash, MDView Video
DKDaniel KuritzkesMDVideoHIVGlobal HIV Clinical Forum 2018What is the Virological support for reduced drug regimens? | Daniel Kuritzkes, MDView Video
MSMauro SchechterMD, PhDVideoHIVGlobal HIV Clinical Forum 2018State of the ART: Integrase Inhibitors (clinical overview) | Mauro Schechter, MD, PhDView Video
OSOmar SuedMSc, MD, PhDVideoHIVBrazilian HIV Clinical Forum 2018Reduced drug regimens - their place in routine practice | Omar Sued, MSc, MD, PhDView Video
ESEduardo SprinzMDVideoHIVBrazilian HIV Clinical Forum 2018Clinical Case presentation | Eduardo SprinzView Video
CBCarlos BritesMD, PhDVideoHIVBrazilian HIV Clinical Forum 2018Optimal use of Integrase Inhibitors in routine clinical practice | Carlos Brites, MD, PhDView Video
VideoHIVBrazilian HIV Clinical Forum 2018Clinical Case presentation | Fabianna Bahia, MD, PhDView Video
CBCharles BoucherMD, PhDVideoHIVBrazilian HIV Clinical Forum 2018Resistance Characteristics of Integrase Inhibitors | Charles Boucher, MD, PhDView Video
DBDavid BackPhDVideoHIVBrazilian HIV Clinical Forum 2018Pharmacological Characteristics and Delivery Options of the Integrase Inhibitors | David Back, PhDView Video
VideoHIVBrazilian HIV Clinical Forum 2018Transitioning to use of Integrase Inhibitors in Brazil | Estevão NunesView Video
VideoHIVBrazilian HIV Clinical Forum 2018The Integrase Inhibitors drug class: a comparative clinical review | Ian FrankView Video
MNMark NelsonMA, MBBS, FRCPVideoHIVViral Hepatitis and Liver DiseaseRSVInternational Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018Debate: Can we eliminate HCV from Africa? | Mark Nelson, MDView Video
